Table 2 Phase 2 and 3 trials... | American Society of Hematology

Table 2

Phase 2 and 3 trials incorporating novel agent–based consolidation following ASCT

Reference	Treatment schema (x cycles)	No.	Response after ASCT (%)		Response after consolidation (%)	PFS of TTP
26	VTDx4	39	CR	15	49	NR
26	VTDx4	39	VGPR	85	98	NR
28	Lenalidomide x2	577	VGPR	58	69	NR
31	RVDx2	30	CR + sCR	47	50	NR
31	RVDx2	30	>VGPR	70	87	NR
30	No consolidation	96	CR	30	30	4-y TTP 29%
	vs		>VGPR	64	64
			>PR	91	91
	VTDx2	121	CR	33	52	4-y TTP 62%
			>VGPR	76	83
			>PR	96	96
27	TD	161	CR	40	47	PFS from start of consolidation 48% at 3 y
	vs		CR + nCR	55	61
			>VGPR	81	88
	VTD	160	CR	49	61	PFS from start of consolidation 60% at 3 y
			CR + nCR	63	73
			>VGPR	86	92
29	No consolidation	183	>nCR	21	35	PFS from start of randomization 20 mo
	vs		>VGPR	39	57
			>PR	89	96
	IV weekly bortezomib (20 infusions)	187	>nCR	20	45	PFS from start of randomization 27 mo
			>VGPR	40	71
			>PR	91	96

Reference	Treatment schema (x cycles)	No.	Response after ASCT (%)		Response after consolidation (%)	PFS of TTP
26	VTDx4	39	CR	15	49	NR
26	VTDx4	39	VGPR	85	98	NR
28	Lenalidomide x2	577	VGPR	58	69	NR
31	RVDx2	30	CR + sCR	47	50	NR
31	RVDx2	30	>VGPR	70	87	NR
30	No consolidation	96	CR	30	30	4-y TTP 29%
	vs		>VGPR	64	64
			>PR	91	91
	VTDx2	121	CR	33	52	4-y TTP 62%
			>VGPR	76	83
			>PR	96	96
27	TD	161	CR	40	47	PFS from start of consolidation 48% at 3 y
	vs		CR + nCR	55	61
			>VGPR	81	88
	VTD	160	CR	49	61	PFS from start of consolidation 60% at 3 y
			CR + nCR	63	73
			>VGPR	86	92
29	No consolidation	183	>nCR	21	35	PFS from start of randomization 20 mo
	vs		>VGPR	39	57
			>PR	89	96
	IV weekly bortezomib (20 infusions)	187	>nCR	20	45	PFS from start of randomization 27 mo
			>VGPR	40	71
			>PR	91	96

nCR, near complete response; sCR, stringent CR.